Australia - English - Department of Health (Therapeutic Goods Administration)

orion laboratories pty ltd t/a perrigo australia - nicotine polacrilex, quantity: 13.33 mg (equivalent: nicotine, qty 2 mg) - tablet, uncoated - excipient ingredients: aspartame; xanthan gum; mannitol; sodium alginate; sodium carbonate; magnesium stearate; potassium bicarbonate; flavour - relief of nicotine withdrawal symptoms including cravings associated with smoking cessation. nicotine lozenges may also be used as part of a smoking reduction strategy by smokers who are unable or not ready to stop smoking abruptly as a step towards stopping smoking. if possible, when stopping smoking, should be used in conjunction with behavioural support program.

Australia - English - Department of Health (Therapeutic Goods Administration)

orion laboratories pty ltd t/a perrigo australia - nicotine polacrilex, quantity: 13.33 mg (equivalent: nicotine, qty 2 mg) - tablet, uncoated - excipient ingredients: mannitol; sodium carbonate; xanthan gum; potassium bicarbonate; sodium alginate; magnesium stearate; aspartame; flavour - relief of nicotine withdrawal symptoms including cravings associated with smoking cessation. nicotine lozenges may also be used as part of a smoking reduction strategy by smokers who are unable or not ready to stop smoking abruptly as a step towards stopping smoking. if possible, when stopping smoking, should be used in conjunction with behavioural support program.

Australia - English - Department of Health (Therapeutic Goods Administration)

orion laboratories pty ltd t/a perrigo australia - nicotine polacrilex, quantity: 13.33 mg (equivalent: nicotine, qty 2 mg) - tablet, uncoated - excipient ingredients: mannitol; potassium bicarbonate; aspartame; sodium alginate; sodium carbonate; magnesium stearate; xanthan gum; flavour - relief of nicotine withdrawal symptoms including cravings associated with smoking cessation. nicotine lozenges may also be used as part of a smoking reduction strategy by smokers who are unable or not ready to stop smoking abruptly as a step towards stopping smoking. if possible, when stopping smoking, should be used in conjunction with behavioural support program.

Australia - English - Department of Health (Therapeutic Goods Administration)

orion laboratories pty ltd t/a perrigo australia - nicotine polacrilex, quantity: 13.33 mg (equivalent: nicotine, qty 2 mg) - tablet, uncoated - excipient ingredients: mannitol; xanthan gum; potassium bicarbonate; magnesium stearate; sodium carbonate; sodium alginate; aspartame; flavour - relief of nicotine withdrawal symptoms including cravings associated with smoking cessation. nicotine lozenges may also be used as part of a smoking reduction strategy by smokers who are unable or not ready to stop smoking abruptly as a step towards stopping smoking. if possible, when stopping smoking, should be used in conjunction with behavioural support program.

Australia - English - Department of Health (Therapeutic Goods Administration)

orion laboratories pty ltd t/a perrigo australia - nicotine polacrilex, quantity: 26.66 mg (equivalent: nicotine, qty 4 mg) - tablet, uncoated - excipient ingredients: mannitol; sodium carbonate; aspartame; potassium bicarbonate; sodium alginate; xanthan gum; magnesium stearate; flavour - relief of nicotine withdrawal symptoms including cravings associated with smoking cessation. nicotine lozenges may also be used as part of a smoking reduction strategy by smokers who are unable or not ready to stop smoking abruptly as a step towards stopping smoking. if possible, when stopping smoking, should be used in conjunction with behavioural support program.

Australia - English - Department of Health (Therapeutic Goods Administration)

haleon australia pty ltd - nicotine polacrilex, quantity: 28.4 mg - gum, chewing - excipient ingredients: glycerol; xylitol; menthol; acacia; sorbitol; mannitol; titanium dioxide; acesulfame potassium; purified talc; sodium carbonate; carnauba wax; calcium carbonate; sucralose; flavour; butylated hydroxytoluene; polyvinyl acetate; glycerol ester of partially hydrogenated gum rosin; microcrystalline wax; polyisobutylene; synthetic terpene resin; hydrogenated vegetable oil; mono- and di- glycerides - relief of nicotine withdrawal symptoms including cravings associated with smoke cessation. nicabate coated gum extra mint may also be used as part of a smoking reduction strategy by smokers who are unable or not ready to stop smoking abruptly as a step towards stopping completely.

Australia - English - Department of Health (Therapeutic Goods Administration)

haleon australia pty ltd - nicotine polacrilex, quantity: 14.2 mg - gum, chewing - excipient ingredients: sorbitol; menthol; acesulfame potassium; purified talc; carnauba wax; glycerol; mannitol; calcium carbonate; acacia; sucralose; titanium dioxide; sodium carbonate; xylitol; butylated hydroxytoluene; polyvinyl acetate; glycerol ester of partially hydrogenated gum rosin; microcrystalline wax; polyisobutylene; synthetic terpene resin; hydrogenated vegetable oil; mono- and di- glycerides; flavour - relief of nicotine withdrawal symptoms including cravings associated with smoke cessation. nicabate coated gum extra mint may also be used as part of a smoking reduction strategy by smokers who are unable or not ready to stop smoking abruptly as a step towards stopping completely.

Australia - English - Department of Health (Therapeutic Goods Administration)

orion laboratories pty ltd t/a perrigo australia - nicotine polacrilex, quantity: 26.66 mg (equivalent: nicotine, qty 4 mg) - tablet, uncoated - excipient ingredients: aspartame; sodium alginate; xanthan gum; potassium bicarbonate; magnesium stearate; sodium carbonate; mannitol; flavour - relief of nicotine withdrawal symptoms including cravings associated with smoking cessation. nicotine lozenges may also be used as part of a smoking reduction strategy by smokers who are unable or not ready to stop smoking abruptly as a step towards stopping smoking. if possible, when stopping smoking, should be used in conjunction with behavioural support program.

Australia - English - Department of Health (Therapeutic Goods Administration)

orion laboratories pty ltd t/a perrigo australia - nicotine polacrilex, quantity: 26.66 mg (equivalent: nicotine, qty 4 mg) - tablet, uncoated - excipient ingredients: sodium alginate; potassium bicarbonate; magnesium stearate; sodium carbonate; mannitol; xanthan gum; aspartame; flavour - relief of nicotine withdrawal symptoms including cravings associated with smoking cessation. nicotine lozenges may also be used as part of a smoking reduction strategy by smokers who are unable or not ready to stop smoking abruptly as a step towards stopping smoking. if possible, when stopping smoking, should be used in conjunction with behavioural support program.

Australia - English - Department of Health (Therapeutic Goods Administration)

orion laboratories pty ltd t/a perrigo australia - nicotine polacrilex, quantity: 26.66 mg (equivalent: nicotine, qty 4 mg) - tablet, uncoated - excipient ingredients: xanthan gum; mannitol; sodium carbonate; sodium alginate; aspartame; potassium bicarbonate; magnesium stearate; flavour - relief of nicotine withdrawal symptoms including cravings associated with smoking cessation. nicotine lozenges may also be used as part of a smoking reduction strategy by smokers who are unable or not ready to stop smoking abruptly as a step towards stopping smoking. if possible, when stopping smoking, should be used in conjunction with behavioural support program.